Janssen Pharmaceutica Nv

Merck Sharp + Dohme Corp.

Joan M Pierce

James Patrick Edwards

David A Kummer

Wei Xiao

Ronald L Wolin

Aihua Wang

Neelakandha S Mani

Jeffrey John Hale

Hariharan Venkatesan

Kevin Douglas Kreutter

J Guy Breitenbucher

Kristi A Leonard

Steven D Goldberg

Maud J Urbanski

John M Keith

Natalie Anne Hawryluk

Xiaohu Deng

Xiaohua Xue

Anne Fourie

Rachel T Nishimura

Shouwu Miao

Craig R Woods

Richard Apodaca

Petr Vachal

Umar Maharoof

Kent Barbay

Mark Seierstad

Jeffrey E Merit

Alison L Chambers

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Methylene linked quinolinyl modulators of ROR&#x3b3;t

The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Growing community of inventors

San Diego, CA, United States of America

Joan M Pierce